An investment bank was looking to invest into a biotechnology company developing several novel products for orphan indications. The bank needed a detailed understanding of the opportunities, risks of the pipeline as well as the capabilities, skills of the biotech company’s scientific and management teams.
PharmaVentures conducted an on-site visit to review the target company’s facilities and capabilities as well as their consultants analysis of the target markets, commercial, developmental and regulatory risks of the pipeline products. Previous decisions of the management were also reviewed for outcome and future impact. PharmaVentures provided its client with a detailed due diligence report describing the size of the investment opportunity and flagged significant risks to be mitigated. Additionally, PharmaVentures provided recommendations for managerial improvements.